MedPath

A randomised study of continuous infusional 5-Fluorouracil (5FU) with or without mitomycin-C in patients with neuroendocrine tumours

Completed
Conditions
euroendocrine tumours
Cancer
Malignant neoplasm of other endocrine glands and related structures
Registration Number
ISRCTN53478221
Lead Sponsor
The Royal Marsden NHS Foundation Trust (UK)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Histological evidence of neuroendocrine tumours not amenable to surgery or radiotherapy
2. Patients evaluable for response must have bi-dimensionally measurable disease as assessed by chest X-ray or computed tomography (CT) scan
3. This disease must be outside previously irradiated areas

Exclusion Criteria

Not provided at time of registration

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Response rate<br>2. Toxicity<br>3. Time to disease progression<br>4. Survival<br>5. Quality of life
Secondary Outcome Measures
NameTimeMethod
o secondary outcome measures
© Copyright 2025. All Rights Reserved by MedPath